May 20, 2026 | Read online

Get A First Look: See Why (HYFT) Just Hit This Morning’s Radar

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Market Maven Insights Puts MindWalk Holdings Corp. (NASDAQ: HYFT) #1 On Today’s Watchlist—Wednesday, May 20, 2026

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

Our Full Breakdown of (HYFT) Goes Live Now

Pull Up (HYFT) While It’s Still Early…

May 20, 2026

Get A First Look: See Why (HYFT) Just Hit This Morning’s Radar

Dear Reader,

Most artificial intelligence platforms in biotechnology are designed to sift through enormous amounts of genetic data, searching for patterns and similarities. But finding patterns is not the same as understanding which biological signals actually drive therapeutic outcomes.

MindWalk Holdings Corp. (NASDAQ: HYFT) was built around a different concept.

Instead of relying primarily on sequence matching, the company’s proprietary HYFT® technology is designed to identify the functional elements of biology—the conserved subsequences that influence how proteins behave and interact within living systems. By focusing on biological function rather than sequence alone, (HYFT) is attempting to uncover relationships that traditional AI models may overlook.

That differentiated approach is beginning to gain traction.

In the third quarter of fiscal 2026, (HYFT) reported revenue of $4.2M CAD, up 52% year over year. The company is also advancing three internal therapeutic programs, including a GLP-1 candidate that demonstrated stronger in vitro activity than semaglutide.

At the same time, (HYFT) has moved approximately 40% since late March 2026, reaching $1.40 on May 11, according to Barchart.

According to TipRanks, two analysts currently maintain price targets that imply roughly 300% upside potential from recent levels.

Technical momentum has also strengthened. Barchart reports that (HYFT) is currently triggering multiple bullish indicators, including the 20-day moving average, the 20/50-day moving average crossover, and the 50-day moving average.

When accelerating revenue growth, expanding therapeutic development, constructive technical signals, and bullish analyst targets begin to align, the result is often a story that warrants closer attention.

That is why (HYFT) has moved to the top of our watchlist heading into Wednesday, May 20, 2026.

A New Era of AI-Driven Therapeutics Is Taking Shape at (HYFT)

MindWalk Holdings Corp. (NASDAQ: HYFT) is a Bio-Native AI company focused on transforming the way biologic dr-ugs are discovered and developed. The company combines proprietary artificial intelligence, large-scale biological datasets, and integrated wet-lab capabilities to help pharmaceutical and biotechnology companies identify and optimize therapeutic candidates more efficiently. MindWalk’s technology has been used by teams across 19 of the top 20 global pharmaceutical companies, and management states that more than 15 molecules discovered using its platform have advanced into clinical development.

At the center of the company’s platform is HYFT® (Hyperdimensional Functional Technology), a patented system that converts sequence, structure, function, and scientific literature into a unified computational language. This technology powers LensAI™, MindWalk’s flagship software platform, which is designed to perform rapid epitope mapping, de novo molecular design, in silico vaccine discovery, and population-scale biologics analytics.

(HYFT) generates revenue through multiple channels, including AI-powered discovery services, enterprise software subscriptions, strategic partnerships, and the development of proprietary therapeutic assets. In 2026, the company announced its first one-year enterprise LensAI contract, marking a shift toward recurring software revenue.

Beyond its commercial platform, (HYFT) is advancing internal programs in areas such as dengue, influenza, metabolic health, and GLP-1-related therapeutics. By integrating advanced AI with laboratory validation, the company aims to reduce the cost and timeline associated with bringing new biologic medicines to market.

(HYFT) Is Targeting the Fast-Growing Intersection of AI and Biotechnology

MindWalk Holdings Corp. (NASDAQ: HYFT) is positioned within the Healthcare sector and Biotechnology industry, but the company’s broader potential lies at the convergence of artificial intelligence, computational biology, and dr-ug discovery.

This emerging category combines artificial intelligence, large-scale biological data, and laboratory validation to improve how new therapies are identified and developed. Rather than functioning solely as a traditional biotech company, (HYFT) is building an integrated platform business that generates revenue through discovery services, enterprise software, strategic partnerships, and internally developed therapeutic assets.

The broader market potential is substantial. According to Global Market Insights, the global artificial intelligence in dr-ug discovery market is projected to grow from approximately $4.0B in 2026 to $43.9B by 2035, representing a compound annual growth rate of roughly 30.5%. Growth is being driven by pharmaceutical companies seeking to reduce the cost, risk, and time associated with developing new medicines.

(HYFT)’s commercial model aligns directly with several of the fastest-growing segments within this market:

AI-powered dr-ug discovery software
Biologics and antibody engineering
Nanobody and multispecific therapeutic design
Vaccine discovery
Enterprise SaaS licensing
Proprietary therapeutic development

The company’s HYFT® and LensAI™ platforms are designed to analyze sequence, structure, function, and scientific literature simultaneously, allowing researchers to identify targets and optimize molecules with greater precision. This approach positions (HYFT) to benefit from the growing convergence of software economics and biotechnology innovation.

From an analytical standpoint, (HYFT) offers exposure to multiple industry themes at once: the continued expansion of artificial intelligence, increasing adoption of computational biology, rising pharmaceutical outsourcing, and the growing demand for more efficient therapeutic development. As capital and strategic partnerships continue to flow into TechBio, companies with differentiated platforms and recurring software revenue models may attract increasing attention.

2026 Developments Continue to Expand (HYFT)’s AI-Powered Dr-ug Discovery Strategy

Throughout 2026, MindWalk Holdings Corp. (NASDAQ: HYFT) has announced a series of milestones that point to growing momentum across its commercial operations, proprietary HYFT® and LensAI™ platforms, and internally developed therapeutic programs.

First LensAI™ Enterprise Contract Signed: (HYFT) announced the signing of its first annual enterprise agreement for LensAI™, providing a pharmaceutical customer with ongoing access to the company’s AI-driven dr-ug discovery platform. This milestone is significant because it expands the company’s business model beyond project-based services and into recurring software revenue.

Third Quarter Fiscal 2026 Results Reported: The company reported 52% year-over-year revenue growth to approximately $4.2M, with U.S. revenue doubling to $2.6M. Management also highlighted progress in its dengue, influenza, and GLP-1 therapeutic programs and emphasized the growing contribution of its AI platform to commercial operations.

HYFT® Applied to Portfolio Risk Detection: (HYFT) introduced a new application of its HYFT® technology designed to detect “functional adjacency,” helping pharmaceutical companies identify molecules that may carry competitive or intellectual property risks despite having different sequences.

Breakthrough Discovery Targeting TDP-43: The company announced the discovery and validation of novel antibodies and intrabodies targeting pathogenic TDP-43, a protein linked to ALS, frontotemporal dementia, and other neurodegenerative disorders. The milestone demonstrated the potential of LensAI™ and HYFT® to identify highly specific therapeutic candidates in challenging disease areas.

Taken together, these milestones suggest that (HYFT) is advancing on multiple fronts simultaneously, including scientific validation, enterprise commercialization, and internal pipeline development.

7 Key Factors Putting HYFT at the Top of Our Watchlist for Wednesday, May 20, 2026

1. Technical Momentum Building: Barchart currently shows (HYFT) triggering the 20-day moving average, 20/50-day crossover, and 50-day moving average.

2. Shares Have Already Started Moving: Since late March 2026, HYFT has advanced approximately 40%, reaching $1.40 on May 11.

3. Analyst Targets Point Higher: Two current analyst targets imply roughly 300% upside potential from recent levels.

4. Revenue Growth Accelerating: Q3 fiscal 2026 revenue climbed to $4.2M CAD, representing 52% growth from $2.7M CAD in the prior-year quarter.

5. Recurring Software Revenue Introduced: The company signed its first annual LensAI™ enterprise agreement, adding a recurring revenue component to the business model.

6. Clinical-Stage Validation Expanding: MindWalk’s platform has contributed to 21+ partner-owned candidates and 10 active Phase 1–3 clinical programs.

7. Differentiated AI Infrastructure: HYFT® and LensAI™ analyze more than 25B biological relationships to uncover functional insights beyond traditional sequence-based methods.

Take a Closer Look at (HYFT) While It’s Still Early…

Taken together, the pieces around (HYFT) appear to be lining up. The company recently reported 52% year-over-year revenue growth, introduced recurring enterprise revenue through its first annual LensAI™ contract, and continues to build clinical validation with more than 21 partner-owned candidates and 10 active Phase 1–3 programs.

Layer in a differentiated AI platform, analyst targets that imply roughly 300% upside potential from recent levels, and a technical setup that remains constructive, and the story begins to attract closer attention.

That combination is why (HYFT) has moved to the top of our watchlist this morning, Wednesday, May 20, 2026.

We have all eyes on (HYFT) right now.

Take a look at (HYFT) while it’s still early.

Also, keep an eye out for our next update—it could be here before the bell rings.

Sincerely,
Tate Remington
Chief Editor, Market Maven Insights

^{MarketMavenInsights.com}^{(“MarketMavenInsights” or “MMI”) is owned by Source Coastal Media LLC, a multi member limited liability company. Data is provided from third-party sources and MMI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MMI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.}

^{Pursuant to an agreement between Source Coastal Media LLC and TD Media LLC, Source Coastal Media LLC has been hired for a period beginning on 05/19/2026 and ending on 05/20/2026 to publicly disseminate information about (HYFT:US) via digital communications. Under this agreement, TD Media LLC has paid Source Coastal Media LLC seven thousand five hundred USD (“Funds”). These Funds were part of the seventy five thousand USD funds that TD Media LLC received from a third party named Bergskogar Limit who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

^{Neither Source Coastal Media LLC, TD Media LLC and their member own shares of (HYFT:US).}

^{Please see important disclosure information here:}^{https://marketmaveninsights.com/disclosure/hyft-j8cgl/#details}